Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PROKIDNEY CORP. (PROK)

ProKidney Q2 2026 net loss widens to $46.4 million as R&D spending rises

Negative Impact 3 of 5 earnings Written later

ProKidney reported a second-quarter 2026 net loss before noncontrolling interest of $46.4 million, up from $37.0 million a year earlier, as research and development expenses rose to $36.1 million from $25.9 million, mainly on the Phase 3 PROACT 1 study. Cash, cash equivalents and marketable securities fell to $181.6 million from $224.9 million at March 31, 2026, and the company said this supports operations into mid-2027. Shareholders face a larger loss per share and a lower cash balance, though the company completed enrollment for the accelerated approval analysis.

Key points

  • Net loss per Class A share was $0.15 for the quarter, compared with $0.13 a year earlier
  • Revenue was $150 thousand, compared with $221 thousand in the second quarter of 2025
  • Cash, cash equivalents and marketable securities totaled $181.6 million at June 30, 2026, down from $224.9 million at March 31, 2026
  • Kenneth Locke was appointed Chief Technical Officer in June 2026; topline results from the PROACT 1 accelerated approval analysis are anticipated in Q2 2027

The filing

CompanyPROKIDNEY CORP. (PROK)
Form8-K, current report
Filed with the SECAug 10, 2026, 4:11 PM ET
Accession number0001193125-26-342397

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.